Resources

Resources

Gross-to-Net 2021: Benchmark Survey Report

In the past year, COVID-19 has expedited efforts for pharmaceutical manufacturers to adopt improved and automated solutions to accurately manage their Gross-to-Net (GTN) forecasting and accrual processes. We polled 40 life sciences manufacturers from across the United States to gauge how they are adjusting to recent changes by asking about motivations, methods, and current blindspots involved in their GTN processes and methodologies. This report shares these responses, measuring industry trends and successful practices that can help manage GTN in 2021 and beyond.

Download now!

adapt analytics bars bell books magnify chart connections marker meds pills search computer paper webcast article blog ebook distribute hand payer heart market Asset 69 Asset 65 Asset 64 Asset 68 Asset 67 Asset 66 Asset 63 decrease expand builder close dart data demand increase index lock locked meter open order pharma pill plot prescription revenue scorecard service shake unlocked Asset 61 Asset 60 Asset 71 icon-distribution-distribution-contract-management icon-distribution-distribution-data-refinery icon-distribution-inventory-analytics icon-distribution-retail-analytics icon-patient-patient-data-refinery icon-patient-patient-services-analytics icon-patient-specialty-pharmacy-analytics icon-payer-340b-analytics icon-payer-analytics icon-payer-g2n icon-payer-government-pricing icon-payer-rebate-management Asset 1 hand hand hand hand hand hand hand hand hand hand hand